Oral Antidiabetic Drugs Market

Diabetes mellitus is a group of a metabolic disorder caused when the body is unable to produce required quantity of Insulin. Insulin is a hormone secreted by beta cells of the islet of Langerhans of the pancreas. Various symptoms associated with diabetes disorder include recurrent urination, increased thirst, and hunger. Diabetes can cause much chronic complication if left untreated. Some of them include acute complications like diabetic ketoacidosis, chronic kidney failure, foot ulcers, and damage to the eyes.

Oral Antidiabetic Drugs Market contains market size and forecasts of Oral Antidiabetic Drugs in global, including the following market information:

• Global Oral Antidiabetic Drugs Market Revenue, 2017-2022, 2023-2028, ($ millions)
• Global Oral Antidiabetic Drugs Market Sales, 2017-2022, 2023-2028, (K Units)
• Global top five Oral Antidiabetic Drugs companies in 2021 (%)

The global Oral Antidiabetic Drugs market was valued at 1897.4 million in 2021 and is projected to reach US$ 2328.3 million by 2028, at a CAGR of 3.0% during the forecast period.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

Sulfonylureas Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Oral Antidiabetic Drugs include Eli Lilly, Abbott, Biocon, Sanofi, Sunpharma, Novartis, Novo Nordisk, Merck and Pfizer, etc. In 2021, the global top five players have a share approximately % in terms of revenue.

We surveyed the Oral Antidiabetic Drugs manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Oral Antidiabetic Drugs Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (K Units)

Global Oral Antidiabetic Drugs Market Segment Percentages, by Type, 2021 (%)

• Sulfonylureas
• Meglitinides
• Alpha-glucosidase inhibitors

Global Oral Antidiabetic Drugs Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (K Units)

Global Oral Antidiabetic Drugs Market Segment Percentages, by Application, 2021 (%)

• Hospitals
• Clinics
• Others

Global Oral Antidiabetic Drugs Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (K Units)

Global Oral Antidiabetic Drugs Market Segment Percentages, By Region and Country, 2021 (%)

• North America
• US
• Canada
• Mexico
• Europe
• Germany
• France
• U.K.
• Italy
• Russia
• Nordic Countries
• Benelux
• Rest of Europe
• Asia
• China
• Japan
• South Korea
• Southeast Asia
• India
• Rest of Asia
• South America
• Brazil
• Argentina
• Rest of South America
• Middle East & Africa
• Turkey
• Israel
• Saudi Arabia
• UAE
• Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

• Key companies Oral Antidiabetic Drugs revenues in global market, 2017-2022 (Estimated), ($ millions)
• Key companies Oral Antidiabetic Drugs revenues share in global market, 2021 (%)
• Key companies Oral Antidiabetic Drugs sales in global market, 2017-2022 (Estimated), (K Units)
• Key companies Oral Antidiabetic Drugs sales share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

• Eli Lilly
• Abbott
• Biocon
• Sanofi
• Sunpharma
• Novartis
• Novo Nordisk
• Merck
• Pfizer
• Huadong Medicine Co.,Ltd.
• Lepu Medical
• Hengrui Medicine